Grant: Discovery Grants Program - Individual
McGill University
$36,000.00
Regulation and targeting of central somatostatin receptors
EF 2007-08
Résumé
Somatostatin is a member of the neuropeptide family of signaling molecules that function as neurotransmitters in the brain and as hormones throughout the body. The actions of somatostatin are mediated through five specific receptor molecules. As is the case for almost all neuropeptide receptors, they belong to the large family of G protein-coupled receptors. These receptors transmit the extracellular signal; e.g. provided by somatostatin, inside the cells and induce a cascade of reactions on the part of the target cells. In order to fulfill this function, receptor molecules have to be delivered to the cell surface. However, so far only a few studies have addressed how cells control the availability of individual receptor types at their surface. Recent research has shown that cell surface delivery of a given type of receptor cannot be taken for granted. Instead, there are marked differences between receptor subtypes, e.g. for somatostatin, in their delivery from intracellular stores to the cell surface in the absence of ligand and in the regulation of their availability at the surface by the ligand. Therefore, I propose to investigate how cells regulated by somatostatin control the availability and types of somatostatin receptors at their surface. Thereby, they effectively regulate their sensitivity to the neuropeptide and, by extension, to drugs acting at the cognate receptors. Somatostatin has been shown to play a critical role in the control of hormone release from the pituitary gland by the brain and in fine tuning other neurotransmitter and hormonal systems. Dysfunctions of the somatostatin system are frequently caused by neuroendocrine tumours of the pituitary or the gastro-intestinal system and have been implicated in a number of disorders such as acromegaly, gigantism, Alzheimer's disease and schizophrenia. The proposed studies will lead to a deeper insight into the mechanisms regulating the sensitivity of the somatostatin system and, by analogy, other neuropeptide signaling systems, potentially breaking ground for the design of more effective drugs and the development of new therapeutic approaches.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
327327-2006
Name nom
Stroh, Thomas
Department département
Neurology and Neurosurgery
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2006
Award amount
36000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Partie
2
Nb partie
3
Application title
Regulation and targeting of central somatostatin receptors
Keyword
NA
Application summary
Somatostatin is a member of the neuropeptide family of signaling molecules that function as neurotransmitters in the brain and as hormones throughout the body. The actions of somatostatin are mediated through five specific receptor molecules. As is the case for almost all neuropeptide receptors, they belong to the large family of G protein-coupled receptors. These receptors transmit the extracellular signal; e.g. provided by somatostatin, inside the cells and induce a cascade of reactions on the part of the target cells. In order to fulfill this function, receptor molecules have to be delivered to the cell surface. However, so far only a few studies have addressed how cells control the availability of individual receptor types at their surface. Recent research has shown that cell surface delivery of a given type of receptor cannot be taken for granted. Instead, there are marked differences between receptor subtypes, e.g. for somatostatin, in their delivery from intracellular stores to the cell surface in the absence of ligand and in the regulation of their availability at the surface by the ligand. Therefore, I propose to investigate how cells regulated by somatostatin control the availability and types of somatostatin receptors at their surface. Thereby, they effectively regulate their sensitivity to the neuropeptide and, by extension, to drugs acting at the cognate receptors. Somatostatin has been shown to play a critical role in the control of hormone release from the pituitary gland by the brain and in fine tuning other neurotransmitter and hormonal systems. Dysfunctions of the somatostatin system are frequently caused by neuroendocrine tumours of the pituitary or the gastro-intestinal system and have been implicated in a number of disorders such as acromegaly, gigantism, Alzheimer's disease and schizophrenia. The proposed studies will lead to a deeper insight into the mechanisms regulating the sensitivity of the somatostatin system and, by analogy, other neuropeptide signaling systems, potentially breaking ground for the design of more effective drugs and the development of new therapeutic approaches.